CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

DOI: 10.1186/s40880-019-0374-8

Keywords: CMAB009, Cetuximab, Irinotecan, Second-line, mCRC, EGFR, KRAS, Immunogenicity, Fluoropyrimidine, Oxaliplatin failure

Full-Text   Cite this paper   Add to My Lib

Abstract:

Eligible KRAS wild-type patients were identified at 38 hospitals in Chin

Full-Text